Ceftazdime Avibactum

# Ceftazdime avibactum ## Overview - **Classification**: Cephalosporin (3rd gen) and beta-lactamase inhibitor combination - **Mechanism**: Ceftazidime inhibits bacterial cell wall synthesis. Avibactam restores ceftazidime activity by inhibiting various beta-lactamases, including Ambler Class A, C, and some D enzymes. ## Primary Indications 1. **Complicated Intra-abdominal Infections (cIAI)** - Used in combination with metronidazole for Gram-negative coverage. 2. **Complicated Urinary Tract Infections (cUTI)** - Including pyelonephritis. 3. **Hospital-acquired bacterial pneumonia (HABP)** and **Ventilator-associated bacterial pneumonia (VABP)**. ## Adult Dosing ### Standard Dosing **cIAI, cUTI, HABP/VABP** - **Dose**: **2.5 g** (ceftazidime **2 g** / avibactam **0.5 g**) - **Frequency**: Every **8 hours** - **Route**: Intravenous (IV) infusion over **2 hours** - **Duration**: 5 to 14 days (cIAI/cUTI), 7 to 14 days (HABP/VABP) ### Dose Adjustments - **Renal Impairment**: Dose adjustments are CRITICAL. - CrCl >50 mL/min: **2.5 g** IV q8h - CrCl 31-50 mL/min: **1.25 g** IV q8h - CrCl 16-30 mL/min: **0.94 g** IV q8h - CrCl 6-15 mL/min: **0.63 g** IV q8h - CrCl ≤5 mL/min (ESRD on HD): **0.94 g** IV single dose, then **0.31 g** IV q24h. Administer after hemodialysis on dialysis days. - **Hepatic Impairment**: No dose adjustment necessary. - **Elderly Patients**: Dose based on renal function, no specific age-related adjustment. ## Pediatric Dosing ### Neonates (0-28 days) - **Special Notes**: Safety and effectiveness have not been established in patients younger than **3 months of age**. ### Infants (3-12 months) - **Indication**: cIAI (in combination with metronidazole), cUTI, HABP/VABP - **Dose**: **62.5 mg/kg** (ceftazidime **50 mg/kg** / avibactam **12.5 mg/kg**) - **Frequency**: Every **8 hours** - **Maximum**: **2.5 g** (ceftazidime **2 g** / avibactam **0.5 g**) per dose - **Special Notes**: Administer IV over **2 hours**. ### Children (1-12 years) - **Indication**: cIAI (in combination with metronidazole), cUTI, HABP/VABP - **Dose**: **62.5 mg/kg** (ceftazidime **50 mg/kg** / avibactam **12.5 mg/kg**) - **Frequency**: Every **8 hours** - **Maximum**: **2.5 g** (ceftazidime **2 g** / avibactam **0.5 g**) per dose - **Special Notes**: Administer IV over **2 hours**. ### Adolescents (13-18 years) - **Indication**: cIAI (in combination with metronidazole), cUTI, HABP/VABP - **Dose**: Use adult dose, **2.5 g** (ceftazidime **2 g** / avibactam **0.5 g**) - **Frequency**: Every **8 hours** - **Maximum**: **2.5 g** (ceftazidime **2 g** / avibactam **0.5 g**) per dose ## Safety Information ### Contraindications - **Absolute**: Known serious hypersensitivity to ceftazidime-avibactam, other cephalosporins, or any beta-lactam antibacterial drugs. ### Common Adverse Effects - **Very Common (>10%)**: Nausea, vomiting, diarrhea, headache, fever. - **Common (1-10%)**: Abdominal pain, rash, increased LFTs, phlebitis at infusion site. - **Serious but Rare**: Seizures (especially with renal impairment), *Clostridioides difficile*-associated diarrhea (CDAD), severe hypersensitivity reactions (anaphylaxis, DRESS), hemolytic anemia. ### Key Drug Interactions - **Nephrotoxic Drugs**: Monitor renal function closely if co-administered, as CAZ-AVI is renally eliminated. - **Probenecid**: May increase avibactam concentrations; co-administration is generally not recommended unless benefits outweigh risks. ## Monitoring & Follow-up - **Before Treatment**: Obtain baseline renal function (CrCl), liver function tests (LFTs). - **During Treatment**: Monitor renal function (CrCl) daily or every other day, especially in patients with impaired renal function. Monitor for signs of clinical improvement or worsening. - **Clinical Signs**: Watch for signs of superinfection, *C. difficile* colitis (diarrhea), and any hypersensitivity reactions. ## Clinical Pearls - 💡 **Potent Coverage**: Highly effective against many carbapenem-resistant Enterobacteriaceae (CRE) and multidrug-resistant *Pseudomonas aeruginosa*. - 💡 **Infusion Time**: Always infuse over **2 hours** to optimize pharmacokinetics/pharmacodynamics and reduce infusion-related reactions. - 💡 **Renal Adjustment**: Strict renal dose adjustment is crucial to prevent accumulation and potential neurotoxicity (e.g., seizures). - 💡 **No Gram-positive/Anaerobe coverage**: Does not cover MRSA. For cIAI, co-administer with metronidazole for anaerobic coverage. > **⚠️ Important**: This information is for educational purposes only. Always consult current prescribing information, local guidelines, and clinical judgment before prescribing.